bluuebunny/crossref_metadata_2025_split huggingface dataset:
Pediatric injuries and poisonings associated with detergent packets: results from the Canadian Hospitals Injury Reporting and Prevention Program (CHIRPP), 2011–2023
Authors: Zutrauen Sarah , Cheesman James , McFaull Steven R. 
Published: July 2024

Abstract
Background
Detergent packets are common household products; however, they pose a risk of injuries and poisonings, especially among children. This study examined the epidemiological characteristics of pediatric injuries and poisonings related to all types of detergent packets in Canada using emergency department (ED) data from the Canadian Hospitals Injury Reporting and Prevention Program (CHIRPP) database.

Methods
The CHIRPP database was searched for ED visit records for injuries and poisonings related to all types of detergent packets between April 1, 2011 and October 12, 2023 (N = 2,021,814) using variable codes and narratives. Data for individuals aged 17 years and younger were analyzed descriptively. Temporal trends in the number of detergent packet-related injuries and poisonings per 100,000 CHIRPP cases were assessed using Joinpoint regression and annual percent change (APC). A proportion ratio and 95% confidence intervals (CI) were calculated to compare the proportion of detergent packet-related cases in CHIRPP during two 34-months periods, pre-COVID-19 pandemic and after the beginning of the pandemic.

Results
There were 904 detergent packet-related cases among children and youth aged 17 years and younger identified in CHIRPP between April 1, 2011 and October 12, 2023, representing 59.9 cases per 100,000 CHIRPP cases. The majority (86.5%) of cases were among children aged 4 years and younger. Poisonings (58.8%) and eye injuries (30.6%) were the most frequent primary diagnoses. Unintentional ingestion (56.9%) and squeezing/breaking a detergent packet (32.3%) were the most frequent exposure mechanisms. Sixty-five patients (7.2%) were admitted to hospital. The number of detergent packet-related cases per 100,000 CHIRPP cases increased by 5.0% (95% CI 0.8, 10.2) annually between 2012 and 2022. The number of detergent packet-related poisonings per 100,000 CHIRPP cases decreased by 15.3% (95% CI − 22.3, − 10.6) annually between 2015 and 2022, whereas eye injuries showed an average annual percent increase of 16.6% (95% CI 11.2, 23.0) between 2012 and 2022. The proportion of detergent packet-related cases in CHIRPP after the beginning of the pandemic (79.9/100,000 CHIRPP cases) was 1.43 (95% CI 1.20, 1.71) times greater than pre-pandemic (55.7/100,000 CHIRPP cases).

Conclusions
Detergent packet-related injuries and poisonings are a persisting issue. Continued surveillance and prevention efforts are needed to reduce detergent packet-related injuries and poisonings in Canada, particularly among children and youth.
DCE-MRI to distinguish all monoclonal plasma cell disease stages and correlation with diffusion-weighted MRI/PET-based biomarkers in a hybrid simultaneous whole body-2-[18F]FDG-PET/MRI imaging approach
Authors: Jamet Bastien , Necib Hatem , Carlier Thomas , Frampas Eric , Bazin Juliette , Desfontis Paul-Henri , Monnet Aurélien , Bodet-Milin Caroline , Moreau Philippe , Touzeau Cyrille , Kraeber-Bodere Francoise 
Published: July 2024

Abstract
Background
Dynamic contrast-enhanced-MRI (DCE-MRI) is able to study bone marrow angiogenesis in patients with multiple myeloma (MM) and asymptomatic precursor diseases but its role in the management of MM has not yet been established. The aims of this prospective study was to compare DCE-MRI-based parameters between all monoclonal plasma cell disease stages in order to find out discriminatory parameters and to seek correlations with other diffusion-weighted MRI and positron emission tomography (PET)-based biomarkers in a hybrid simultaneous whole-body-2-[18F]fluorodeoxyglucose (FDG)-PET/MRI (WB-2-[18F]FDG-PET/MRI) imaging approach.

Methods
Patients with newly diagnosed Monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM) or symptomatic MM according to international myeloma working group and underwent WB-2-[18F]FDG-PET/MRI imaging including bone marrow DCE sequences at the Nantes University Hospital were prospectively enrolled in this study before receiving treatment.

Results
One hundred and sixty-seven patients (N = 167, mean age: 64 years ± 11 [Standard deviation], 66 males) were considered for the analysis. DCE-MRI-based Peak Enhancement Intensity (PEI), Time to PEI (TPEI) and their maximum intensity time ratio (MITR: PEI/TPEI) values were significantly different between the different monoclonal plasma cell disease stages, PEI values increasing and TPEI values decreasing progressively along the spectrum of plasma cell disorders, from MGUS stage to symptomatic multiple myeloma. PEI values were significantly higher in patients with diffuse bone marrow involvement (either in PET or in MRI images) than in those without diffuse bone marrow involvement, unlike TPEI values. PEI and TPEI values were not significantly different between patients with or without focal bone lesions.

Conclusion
Different DCE-MRI-based parameters (PEI, TPEI, MITR) could significantly differentiate all monoclonal plasma cell disease stages and complemented conventional MRI and PET-based biomarkers.
Noneffectiveness of cryostorage duration on clinical and neonatal outcomes after single vitrified-warmed blastocyst transfers
Authors: Baatarsuren Mungunshagai , Jamiyansuren Jambaldorj , Ganbaatar Chinzorig , Sengebaljir Davaakhuu , Erdenekhuyag Belguune , Enkhbaatar Sandag , Mungunsuvd Namsrai , Baljinnyam Lkhagvasuren , Tumur-Ochir Ganjiguur , Amarsaikhan Ariunaa , Dorjpurev Amarjargal , Ganbat Gereltsetseg , Boris Tsogzolmaa , Khangarid Azjargal 
Published: July 2024

Abstract
Background
In the current era of assisted reproductive technology, the strategy of single vitrified-warmed blastocyst transfer (SVBT) is acknowledged for positively impacting clinical outcomes and preventing the risk of multiple conceptions. Previous studies have indicated that blastocyst grade and the day of blastocyst positively correlate with outcomes. Moreover, storage duration has no significant effect on survival rates, clinical outcomes, and neonatal outcomes. However, some researchers express controversial opinions on cryostorage duration, and their findings suggest a negative impact on clinical outcomes. These results remain subject to controversy, and limited studies exist regarding the outcomes after SVBT. Therefore, our study aims to investigate the impact of the day of blastocyst, blastocyst grade, and blastocyst cryostorage duration on clinical and neonatal outcomes following SVBT in patients who underwent clomiphene-citrate-based minimal stimulation.

Material and methods
In this study, retrospective cohort study data collected from June 2015 to April 2023 included 2107 patients with first SVBT cycles who underwent a clomiphene-based minimal ovarian stimulation protocol or a drug-free natural protocol at the Ojinmed IVF Center. Patients were categorized into four groups based on blastocyst cryostorage duration: group 1 (< 2 months, n = 882), group 2 (3–6 months, n = 794), group 3 (7–12 months, n = 187), group 4 (13–24 months, n = 126), and group 5 (25–81 months, n = 118). The patient’s clinical and neonatal outcomes were compared with cryostorage duration after the propensity score matched.

Result
Multivariable logistic regression analysis revealed that prolonged cryostorage duration insignificantly correlated with clinical outcomes. Additionally, neonatal outcomes are not correlated with cryostorage duration.

Conclusions
The patient must consider several parameters when selecting embryos for transfer, including the duration of cryostorage. Our study results show that for the first single vitrified-warmed blastocyst transfer of patients who underwent clomiphene citrate-based minimal stimulation, cryostorage duration does not affect outcomes.
A multicenter phase 1 trial of tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2–positive breast cancer (TUTOR).
Authors: Ahluwalia Manmeet Singh , Ozair Ahmad , Bardhan Mainak , Bellur Shreyas S , Perche Dilanis C. , Starosciak Amy K. , Leon-Ariza Daniel S. , Khosla Atulya Aman , Rubens Muni , Odia Yazmin , Mehta Minesh P. , Kotecha Rupesh , McDermott Michael W , Sandoval-Leon Ana Cristina , Mahtani Reshma L. , Peereboom David M. 
Published: July 2024

TPS2089 Background: 20-40% of HER-2-positive breast cancer patients develop brain metastases (BMs), for which stereotactic radiosurgery (SRS) is used for local disease control. Tucatinib, an oral HER-2-selective tyrosine kinase inhibitor (TKI), has been demonstrated to be safe and efficacious in HER-2-positive breast cancer in combination with capecitabine and trastuzumab. The synergism between these three drugs and radiation may potentially enhance DNA damage, causing increased apoptosis. We hypothesize that this 3-drug therapy, in combination with SRS in patients with HER-2 positive breast cancer BM (BCBM), may be safe and provide superior long-term control of intracranial and systemic disease. Methods: This is a prospective, single-arm, multicenter, ongoing, phase 1 clinical trial. Patients aged 18-80 years, ECOG score 0-2, normal organ function, and up to 10 newly-diagnosed BMs is planned to enroll at six centers in the US. Any number of prior systemic therapies are allowed, except tucatinib and capecitabine. Key exclusion criteria include leptomeningeal metastases, evidence of intra-tumoral or peri-tumoral hemorrhage, and BMs within 5 mm of the optic chiasm/nerve. Patients receive oral tucatinib alongside SRS, followed by a two-week dose-limiting toxicity (DLT) period, and subsequently continue the regimen until disease progression or intolerable toxicity. DLTs are defined by Grade 3 or 4 thrombocytopenia, grade 4 anemia, grade 4 neutropenia lasting more than seven days, febrile neutropenia, and grade 3 non-hematologic toxicity. Primary study endpoint is maximum tolerated dose (MTD) of tucatinib in combinatorial therapy. This de-escalation study starts at 300 mg dose level (DL), with DL-1 250 mg, and DL-2 200 mg, based on a 3 + 3 design. Cohort expansion at MTD is planned to a total of 40 patients. Secondary endpoints include efficacy as determined by response rate, intracranial progression-free survival (PFS), extracranial PFS, overall survival, quality of life as assessed by FACT-Br, toxicity, and neurocognitive function. The trial has been approved by the Institutional Review Board (IRB) and currently is enrolling patients. Clinical trial information: NCT05553522 .
A phase II, multicenter, prospective study of sacituzumab govitecan in recurrent glioblastoma.
Authors: Kelly William , Cordova Christine , Vaillant Brian D. , Balinda Henriette , Michalek Joel , Gilbert Andrea , Floyd John , Brenner Andrew J. 
Published: July 2024

TPS2094 Background: Despite decades of research, glioblastoma (GBM) remains the most common and aggressive primary brain malignancy. GBM has been shown to express trophoblast cell-surface antigen 2 (Trop2) and this expression corelates with proliferation rate, micro vessel density, histological grade and clinical survival1,2. Antibody drug conjugates (ADC) targeting cell surface receptors have been recently shown to produce intracranial response rates of 25-44%%3-5. Sacituzumab Govitecan (SG) consists of an ADC targeting Trop2 attached via linker to a chemotherapy payload, SN-38. In 2020, it received FDA approved for the treatment of metastatic triple-negative breast cancer followed by HR+/HER2- metastatic breast cancer in 2023. Methods: This is a multi-center, open-label, prospective, single-arm phase 2 study using a 2-stage adaptive Bayesian design. Patients with GBM (IDH wild-type), recurrent following standard-of-care chemoradiation, received SG at 10mg/kg IV on days 1 and 8 of a 21 day cycle. Patients were assessed by RANO and CTCAE v5. The primary endpoint was progression-free survival of patients on SG as compared to a historical control of lomustine monotherapy. Enrollment was conducted at UT Health Science Center in San Antonio, Cleveland Clinic and Texas Oncology in Austin. A total of 23 patients have been screened with 3 screen failures and 20 patients enrolled. The study has now entered interim analysis. Trial Registration: This trial (NCT04559230) is enrolled at Clinical Trials.gov as “Sacituzumab Govitecan in Recurrent Glioblastoma”: https://clinicaltrials.gov/study/NCT04559230 Funding: WK and AB have received contracted funding from Gilead. Additional support provided by an NCI Cancer Center Support Grant (P30CA016672) and an Early Clinical Investigator Award through CPRIT (RP210164). References: 1. Ning, S., et al., TROP2 expression and its correlation with tumor proliferation and angiogenesis in human gliomas. Neurol Sci, 2013. 34(10): p. 1745-50; 2. Harvard, B.I.o.M.a., Broad Institute TCGA Genome Data Analysis Center (2016): Correlation between mRNA expression and clinical features; 3.Fabi, A., et al., T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer. Breast, 2018.41: p. 137-143; 4. Jacot, W., et al., Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. Breast Cancer Res Treat, 2016. 157(2): p. 307-318. Clinical trial information: NCT04559230 .
A phase 1/2 dose escalation and expansion study of sonodynamic therapy with SONALA-001 in combination with Exablate 4000 Type 2.0 MR-guided focused ultrasound in patients with progressive or recurrent glioblastoma (rGBM).
Authors: Placantonakis Dimitris , Grabowski Matthew , Burns Terry C. , Butowski Nicholas A. , Fenn Peter , Clanton Ryan , Henry Lenora , Potter Wyatt , Andresen Corina , Marcus Stuart , Benaim Ely 
Published: July 2024

TPS2101 Background: Recurrent glioblastoma (rGBM) is a lethal brain tumor with no effective therapy and an extremely poor prognosis (median survival 6 to 8 months after first recurrence). Sonodynamic therapy (SDT) is a non-invasive combination treatment that utilizes a drug, aminolevulinic acid HCL (SONALA-001), and a device, the Exablate 4000 Type 2.0, to deliver non-ablative MR-guided focused ultrasound (MRgFUS) to tumor. Preclinical studies have shown that SDT-induced sonoluminescence activates protoporphyrin IX (PpIX), which in turn generates reactive oxygen species that lead to tumor cell death and improved survival in animal glioma models. A first-in-human Phase 0 trial (NCT04559685) indicated that SONALA-001 SDT was well-tolerated and not associated with off-target cellular or radiographic effects, and provided direct evidence of reactive oxygen species formation and targeted tumor cell death in recurrent high-grade glioma (rHGG). Methods: SDT-202 is a Phase 1/2 multicenter, open-label, dose escalation and expansion study (NCT05370508) of 10 mg/kg iv SONALA-001 in combination with MRgFUS for SDT in patients with progressive or recurrent GBM. Treatments take place every 4 weeks. In phase 1, sonication energy escalation utilizes an accelerated titration design with a single subject for dose level 1, followed by cohorts 2 and 3 with 3+3 design for additional dose escalation. SONALA-001 is administered 6 to 12 hours prior to MRgFUS treatment. Once the RP2D is determined, Phase 2 dose expansion will enroll approximately 36 additional subjects to assess safety and efficacy of repeated cycles of SONALA-001 SDT at the optimized RP2D. Endpoints of this study are safety evaluation, maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and determination of pharmacokinetic (PK) parameters. The Phase 2 portion will further characterize safety of RP2D along with evaluation of efficacy with PFS6 (mRANO), ORR, CBR, DOR, DOCR, TTR, and OS. Clinical trial information: NCT05370508 .
Evidence Against a Traumatic Brain Injury “July Effect”: An Analysis of 3 160 452 Patients From the National Inpatient Sample
Authors: Gajjar Avi A. , Covell Michael M. , Prem Kumar Rohit , Tang Oliver Y. , Ranganathan Sruthi , Muzyka Logan , Mualem William , Rehman Inaya , Patel Shrey V. , Lavadi Raj Swaroop , Mitha Rida , Lieber Bryan A. , Hamilton D. Kojo , Agarwal Nitin 
Published: July 2024

BACKGROUND AND OBJECTIVES:
The “July Effect” hypothesizes increased morbidity and mortality after the addition of inexperienced physicians at the beginning of an academic year. However, the impact of newer members on neurosurgical teams managing patients with traumatic brain injury (TBI) has yet to be examined. This study conducted a nationwide analysis to evaluate the existence of the “July Effect” in the setting of patients with TBI.

METHODS:
The Healthcare Cost and Utilization Project Central Distributor's National Inpatient Sample data set was queried for patients with TBI using International Classification of Diseases (ICD)-9 and ICD-10 codes. Discharges were included for diagnoses of traumatic epidural, subdural, or subarachnoid hemorrhages. Only patients treated at teaching hospitals were included to ensure resident involvement in care. Patients were grouped into July admission and non-July admission cohorts. A subgroup of patients with neurotrauma undergoing any form of cranial surgery was created. Perioperative variables were recorded. Rates of different complications were assayed. Groups were compared using χ2 tests (qualitative variables) and t-tests or Mann-Whitney U-tests (quantitative variables). Logistic regression was used for binary variables. Gamma log-linked regression was used for continuous variables.

RESULTS:
The National Inpatient Sample database yielded a weighted average of 3 160 452 patients, of which 312 863 (9.9%) underwent surgical management. Patients admitted to the hospital in July had a 5% decreased likelihood of death (P = .027), and a 5.83% decreased likelihood of developing a complication (P < .001) compared with other months of the year. July admittance to a hospital showed no significant impact on mean length of stay (P = .392) or routine discharge (P = .147). Among patients with TBI who received surgical intervention, July admittance did not significantly affect the likelihood of death (P = .053), developing a complication (P = .477), routine discharge (P = .986), or mean length of stay (P = .385).

CONCLUSION:
The findings suggested that there is no “July Effect” on patients with TBI treated at teaching hospitals in the United States.
Gamma Knife Radiosurgery for Hypothalamic Hamartoma: A Multi-Institutional Retrospective Study on Safety, Efficacy, and Complication Profile
Authors: Tripathi Manjul , Sheehan Jason P. , Niranjan Ajay , Ren Lydia , Pikis Stylianos , Lunsford L. Dade , Peker Selcuk , Samanci Yavuz , Langlois Anne Marie , Mathieu David , Lee Cheng Chia , Yang Huai Che , Deng Hansen , Rai Ashutosh , Kumar Narendra , Sahu Jitendra Kuma , Sankhyan Naveen , Deora Harsh 
Published: July 2024

BACKGROUND AND OBJECTIVES:
Gamma knife radiosurgery (GKRS) is a safe and effective treatment option for hypothalamic hamartomas (HH), but there is no consensus opinion on its timing, dosage, and follow-up. The aim of this study was to define the safety, efficacy, outcome, and complication profile of GKRS in this patient population.

METHODS:
This retrospective multicentric study involved 39 patients with the mean age of 16 ± 14.84 years. Early seizures resulted in an earlier age of diagnosis in 97% of patients. At baseline, no endocrine abnormalities were seen in 75% of patients while 18.9% showed precocious puberty (PP). The median target volume was 0.55 cc (0.1-10.00 cc), and a median margin dose of 16 Gy (8.1-20.0 Gy) was delivered in a single session. All patients were evaluated for clinical, endocrinological, and radiological outcomes.

RESULTS:
The median follow-up was 5 (0.1-15) years. The median target volume of the cohort was 0.55 (0.35-1.77) cc. The largest HH was of 10 cc. 24/39 (61.5%) were small HH (Regis I-III). At presentation, 94.8% patients suffered from seizures (87.18% with gelastic seizures). 7/39 patients (17.9%) were presented with both PP and epilepsy. Only one (2.6%) patient presented with PP alone. 29 patients had more than 3-year follow-up. All received ≥16 Gy targeting complete HH. 28% of patients showed regression in HH volume. Patients with Regis grade I-III and longer follow-up (>75 months) showed gradual improvement in seizures. 16/29 patients (55.2%) achieved good seizure control (Engel I/II) while 13 (44.8%) were in Engel III/IV status. Nine patients needed adjuvant treatment because of poor seizure control. Eight patients suffered from transient increase in seizures. One patient developed poikilothermia, and 2 patients developed new onset hormonal deficiency.

CONCLUSION:
GKRS is a safe and effective modality for treatment of HH with significant improvement in seizure control with minimal disruption of endocrine profile. It provides an excellent safety, efficacy, and complication profile, especially for small HH. Latency of results and its adjuvant nature remain the areas of research and breakthroughs among contemporary treatment options.
Mechanisms controlling haemolymph circulation under resting conditions in the Chagas disease vector Rhodnius prolixus
Authors: Villalobos Sambucaro María José , Alzugaray María Eugenia , Ronderos Jorge Rafael 
Published: July 2024

ABSTRACT
Chagas disease vectors can ingest several times their own volume in blood with each meal. This ad libitum feeding causes an intense process of diuresis, inducing the insect to eliminate a large quantity of urine and faeces. To ensure diuresis, the speed of circulation of the haemolymph is increased. The Triatominae circulatory system is quite simple, including the dorsal vessel, which pumps haemolymph in an anterograde direction. The return is caused by peristaltic contractions of the anterior midgut. Triatominae insects can spend several weeks without feeding, meaning that most of the time, the insect is in a resting condition. Although the mechanisms controlling the circulation of the haemolymph during post-prandial diuresis have been largely analysed, the mechanisms controlling it during resting conditions are poorly understood. In this study, we analysed several canonical pathways (i.e. L-type VGCC, GPCR, RyR, IP3R) and a novel system represented by the recently characterized Piezo proteins. Our results show that during the resting condition, haemolymph circulation depends on a cross-talk between myogenic activity, inhibitory and stimulatory cellular messengers, and Piezo proteins. This report also unveils for the first time the existence of a putative Piezo protein in Hemiptera.